<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now? — Newsletter</title>
<style>
:root{
  --bg:#0f172a; --panel:#111827; --ink:#e5e7eb; --muted:#9ca3af; --link:#60a5fa; --btn:#1f2937; --accent:#93c5fd;
}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--ink);font:16px/1.6 system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial}
a{color:var(--link);text-decoration:none} a:hover{text-decoration:underline}
.page{max-width:920px;margin:42px auto;padding:0 16px}
.hdr{display:flex;justify-content:space-between;align-items:center;margin-bottom:16px}
.hdr .title{font-weight:700;color:#c7d2fe}
.hdr .tagline{color:var(--muted);font-size:14px}
.card{background:var(--panel);border:1px solid rgba(255,255,255,.08);border-radius:18px;padding:22px 24px;box-shadow:0 8px 30px rgba(0,0,0,.25)}
h1{margin:0 0 6px;font-size:34px;line-height:1.2}
.meta{color:var(--muted);font-size:14px;margin-bottom:10px}
ul{margin:14px 0 0 22px;padding:0}
li{margin:8px 0}
.btn{display:inline-block;background:var(--btn);color:var(--ink);border:1px solid rgba(255,255,255,.08);padding:8px 12px;border-radius:10px;margin-right:10px}
.btn:hover{background:#374151;text-decoration:none}
.footer{color:var(--muted);text-align:center;margin:28px 0}
.hero{margin:20px 0 26px}
.grid{display:grid;gap:14px}
.grid a{display:block;padding:12px 14px;border-radius:12px;background:var(--panel);border:1px solid rgba(255,255,255,.08)}
.small{font-size:14px;color:var(--muted)}
</style>
<body>
  <div class="page">
    <div class="hdr">
      <div class="title">Daily Finance Newsletter</div>
      <div class="tagline">5–7 key bullets per story</div>
    </div>
    <div class="card">
      <h1>Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?</h1>
      <div class="meta">2025-09-15 15:08:00+00:00 UTC</div>
      <ul>
        <li>In 2025, Lilly expects to record revenues in the range of $60.0 billion to $62.0 billion, indicating an impressive year-over-year growth of more than 30% We believe that LLY has solid growth prospects and a promising por</li>
        <li>Mounjaro and Zepbound account for around 50% of the company’s total revenues.</li>
        <li>Lilly’s stock is up 18% since the second-quarter results, easing some of the recent negative sentiment.</li>
        <li>Competition Heating Up in the Obesity Space The obesity market is expected to expand to $100 billion by 2030, according to data from Goldman Sachs, which means fierce competition is inevitable.</li>
        <li>In 2025, it announced three M&amp;A deals.</li>
        <li>LLY’s Stock Price, Valuation and Estimates Lilly’s stock has declined 2.2% so far this year compared with the industry’s decrease of 0.2%.</li>
        <li>In the ATTAIN-2 study in obese adults with type II diabetes, the highest dose (36 mg) of orforglipron delivered a weight loss of up to an average of 22.9 pounds or 10.5%.</li>
      </ul>
      <div class="hero">
        <a class="btn" href="https://suavir600.github.io/Newsletter/articles/lilly-moves-past-50-day-sma-should-you-consider-buying-the-stock-now/" target="_blank" rel="noopener">Original</a> <a class="btn" href="https://finance.yahoo.com/news/lilly-moves-past-50-day-150800320.html" target="_blank" rel="noopener nofollow">Source</a>
        <a class="btn" href="https://twitter.com/intent/tweet?text=Lilly+Moves+Past+50-Day+SMA%3A+Should+You+Consider+Buying+the+Stock+Now%3F%0A%E2%80%A2+In+2025%2C+Lilly+expects+to+record+revenues+in+the+range+of+%2460.0+billion+to+%2462.0+billion%2C+indicating+an+impressive+year-over-year+growth+of+more+than+30%25+We+believe+that+LLY+has+sol%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Flilly-moves-past-50-day-sma-should-you-consider-buying-the-stock-now%2F" target="_blank" rel="noopener">Share on X</a>
      </div>
    </div>
    <div class="footer">© 2025 · Built from digest_5bullets.md</div>
  </div>
</body>
</html>
